Follow our progress.

Milestones in our journey to reinvent genetic testing.

View full list

Press Releases

Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

December 03, 2014

SAN FRANCISCO, December 3, 2014 – Invitae Corporation, a genetic information company, announced that its testing services are eligible for coverage by two additional payors, Blue Shield of California and the Centers for Medicare and Medicaid Services (CMS). 

“Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” said Lisa Alderson, chief commercial officer of Invitae.  “Since launching just over a year ago, we have grown our volume rapidly by offering high quality genetic testing at an affordable price for payors.”

Currently, Invitae offers clinicians an assay of 216 genes comprising 85 different genetic disorders and 17 targeted panels focused on hereditary cancers, including breast, ovarian, colon and pancreatic cancer, as well as cardiology, hematology, neurology and pediatric panels.  Invitae currently allows physicians a free re-requisition of additional data within the same indication when ordered within 90 days of the date of service.  Importantly, Invitae provides turnaround time of less than three weeks for the substantial majority of its tests.

About Invitae 

Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics. For further information, please visit www.invitae.com

Contact:
Katherine Stueland
pr@invitae.com
415.254.1233

Share

Return to press releases